Articles from Corstasis Therapeutics Inc.

Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for patients with cardiovascular and renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™ (bumetanide nasal spray). ENBUMYST is indicated for the treatment of edema associated with congestive heart failure (CHF), and hepatic and renal disease, including nephrotic syndrome in adults.

Corstasis Therapeutics Inc. (www.corstasis.com), a late clinical-stage innovator of outpatient therapies for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, announced today the appointment of Amin M. Medjamia M.D. as Vice President of Medical Affairs.

Corstasis Therapeutics Inc. (www.corstasis.com), a late clinical-stage innovator of outpatient therapies for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, announced today that the U.S. Patent and Trade Office (USPTO) has allowed a new patent for its proprietary subcutaneous bumetanide formulations expanding its pipeline beyond Enbumyst™ (bumetanide nasal spray) into subcutaneous dose forms.

Corstasis Therapeutics Inc. (www.corstasis.com), a late clinical-stage innovator of therapies that enhance options for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, with the intent of lowering the overall cost of care, today announced that life science executive Sanjeev Narula has joined the company’s Strategic Advisory Board.

Corstasis Therapeutics Inc. (www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid overload, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.

Corstasis Therapeutics Inc., a clinical-stage biotechnology company pioneering outpatient therapies for fluid overload (edema) associated with congestive heart failure (CHF), liver disease, and chronic kidney disease, today announced that data from its pivotal trial of the bumetanide nasal spray (RSQ-777-02) will be presented at the upcoming American Heart Association’s (AHA) annual Scientific Sessions in Chicago, Illinois, November 16-18, 2024.